Exchange: NASDAQ·Updated 12:33 PM EDT
INAB logo

INAB IN8bio Inc

$1.18
$0.0219
(1.89%)
Today
Reported EarningsAug 6
Mkt Cap$11.44M
Vol18,925.00

About INAB

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates for solid and liquid tumors and gamma-delta T cell engagers for cancer and autoimmune diseases. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
42

Bearish Sentiment

How do you feel about INAB?

Advertisement|Remove ads.